AZTA Stock Overview
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$74.29|
|52 Week High||US$124.79|
|52 Week Low||US$61.35|
|1 Month Change||1.38%|
|3 Month Change||-12.91%|
|1 Year Change||-21.19%|
|3 Year Change||91.72%|
|5 Year Change||242.51%|
|Change since IPO||642.90%|
Recent News & Updates
|AZTA||US Life Sciences||US Market|
Return vs Industry: AZTA underperformed the US Life Sciences industry which returned -15.9% over the past year.
Return vs Market: AZTA underperformed the US Market which returned -18.5% over the past year.
|AZTA Average Weekly Movement||7.3%|
|Life Sciences Industry Average Movement||11.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AZTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AZTA's weekly volatility (7%) has been stable over the past year.
About the Company
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows.
Azenta Fundamentals Summary
|AZTA fundamental statistics|
Is AZTA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AZTA income statement (TTM)|
|Cost of Revenue||US$284.78m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||-4.21%|
How did AZTA perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is AZTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AZTA?
Other financial metrics that can be useful for relative valuation.
|What is AZTA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AZTA's PS Ratio compare to its peers?
|AZTA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the peer average (4.1x).
Price to Earnings Ratio vs Industry
How does AZTA's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?
Price-To-Sales vs Industry: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the US Life Sciences industry average (5.2x)
Price to Sales Ratio vs Fair Ratio
What is AZTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||10x|
|Fair PS Ratio||5.4x|
Price-To-Sales vs Fair Ratio: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).
Share Price vs Fair Value
What is the Fair Price of AZTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AZTA ($74.29) is trading below our estimate of fair value ($108.06)
Significantly Below Fair Value: AZTA is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AZTA's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Azenta forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZTA's earnings are forecast to decline over the next 3 years (-103.2% per year).
Earnings vs Market: AZTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AZTA is expected to become profitable in the next 3 years.
Revenue vs Market: AZTA's revenue (20.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: AZTA's revenue (20.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZTA's Return on Equity is forecast to be low in 3 years time (2.2%).
Discover growth companies
How has Azenta performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZTA is currently unprofitable.
Growing Profit Margin: AZTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AZTA is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.
Accelerating Growth: Unable to compare AZTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZTA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).
Return on Equity
High ROE: AZTA has a negative Return on Equity (-0.67%), as it is currently unprofitable.
Discover strong past performing companies
How is Azenta's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AZTA's short term assets ($3.0B) exceed its short term liabilities ($618.0M).
Long Term Liabilities: AZTA's short term assets ($3.0B) exceed its long term liabilities ($76.1M).
Debt to Equity History and Analysis
Debt Level: AZTA is debt free.
Reducing Debt: AZTA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AZTA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AZTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Azenta current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AZTA's dividend (0.54%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.57%).
High Dividend: AZTA's dividend (0.54%) is low compared to the top 25% of dividend payers in the US market (4.24%).
Stability and Growth of Payments
Stable Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: AZTA is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: AZTA is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Schwartz (62 yo)
Dr. Stephen S. Schwartz, also known as Steve, is a Director Azenta US, Inc. He is President and Chief Executive Officer at Azenta US, Inc. He has been Chief Executive Officer of Azenta, Inc. (formerly know...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD5.29M) is below average for companies of similar size in the US market ($USD8.44M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Experienced Management: AZTA's management team is seasoned and experienced (7.9 years average tenure).
Experienced Board: AZTA's board of directors are seasoned and experienced ( 11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AZTA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Azenta, Inc.'s employee growth, exchange listings and data sources
- Name: Azenta, Inc.
- Ticker: AZTA
- Exchange: NasdaqGS
- Founded: 1978
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.530b
- Shares outstanding: 74.43m
- Website: https://www.azenta.com
Number of Employees
- Azenta, Inc.
- 15 Elizabeth Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.